Trials / Completed
CompletedNCT04884191
Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 165 (actual)
- Sponsor
- CTI BioPharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This was an open-label, randomized, dose-finding study in patients with primary or secondary MF (Dynamic International Prognostic Scoring System \[DIPSS\] risk score of Intermediate-1 to High-Risk) who were previously treated with ruxolitinib. The study was designed to support a pacritinib dosage selection decision with evaluation of 3 dosages.
Conditions
- Primary Myelofibrosis
- Post-Polycythemia Vera Myelofibrosis
- Post- Essential Thrombocythemia Myelofibrosis
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pacritinib | Pacritinib |
Timeline
- Start date
- 2017-07-31
- Primary completion
- 2019-09-04
- Completion
- 2019-09-04
- First posted
- 2021-05-12
- Last updated
- 2022-06-01
- Results posted
- 2022-06-01
Locations
62 sites across 8 countries: United States, France, Hungary, Italy, South Korea, Spain, Sweden, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04884191. Inclusion in this directory is not an endorsement.